Patients with metastatic skin melanoma are treated with immune checkpoint inhibitors and targeted BRAF/MEK inhibitors, resulting in durable responses in roughly half of all patients. Uveal melanoma UM is a rarer form of melanoma which arises in the eye but that metastasize in 50% of all cases. Metastatic UM has a poor prognosis and has not benefitted as much by modern therapies as patients with metastatic cutaneous melanoma. Recent phase 2/3 trials by us and others include ICI combination therapies, the bispecific agent tebentafusp and locoregional therapy (isolated or percutaneous hepatic perfusion, PHP/IHP) directed at liver metastases. While these treatments have increased median survival from one to two years, they do not appear to be curative. New treatment arsenals are therefore needed for patients with treatment-resistant skin and uveal melanoma. T cell therapy include tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor expressing T cells (CAR-T). TIL therapy has been offered to patients with metastatic skin melanoma, but only scarcely to patients with UM. We, and others, have shown that TILs do exist in metastatic UM and can be expanded to great numbers for infusion. In this presentation, I will outline some of our characterizations on TILs in metatstatic UM and provide an update on the ongoing clinical trial HAITILS. I will also provide an update on the efforts to start a first trial in Australia trial called PERTIL trial where perkileucel, a hospital manufactured TIL product, will be manufactured and used for patients with therapy resistant skin melanoma. Finally, I will review our ongoing work on CAR-T cells and outline the challenges and possibilities with this type of treatment.